Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fausto Castagnetti

Showing results (81-90 of 158) with videos related to

Pageof 16
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 26, 2006
Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid LeukemiaSimona Soverini, Sabrina Colarossi, Alessandra Gnani, et al.
Blood|July 11, 2009
Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitorsSimona Soverini, Alessandra Gnani, Sabrina Colarossi, et al.
Hematological Oncology|July 21, 2012
Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemiaRoberto Latagliata, Massimo Breccia, Carmen Fava, et al.
Haematologica|March 23, 2010
The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phaseFrancesca Palandri, Fausto Castagnetti, Ilaria Iacobucci, et al.
American Journal of Hematology|June 5, 2025
Outcome of Chronic Myeloid Leukemia Patients Not in Deep Molecular Response: Results From the GIMEMA LabNet CML Network DatabaseFabio Stagno, Rosalba Cucci, Giovanni Marsili, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 4, 2005
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid LeukemiaSimona Soverini, Giovanni Martinelli, Gianantonio Rosti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 5, 2010
Deletions of the derivative chromosome 9 do not influence the response and the outcome of chronic myeloid leukemia in early chronic phase treated with imatinib mesylate: GIMEMA CML Working Party analysisFausto Castagnetti, Nicoletta Testoni, Simona Luatti, et al.
Haematologica|January 16, 2009
The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-upFrancesca Palandri, Fausto Castagnetti, Giuliana Alimena, et al.
Haematologica|July 18, 2012
Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitorsAntonella Russo Rossi, Massimo Breccia, Elisabetta Abruzzese, et al.
Annals of Hematology|April 21, 2018
Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practiceMassimo Breccia, Elisabetta Abruzzese, Fausto Castagnetti, et al.
Pageof 16

Showing results (81-90 of 158) with videos related to

Sort By:
Pageof 16
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 26, 2006
Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid LeukemiaSimona Soverini, Sabrina Colarossi, Alessandra Gnani, et al.
Blood|July 11, 2009
Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitorsSimona Soverini, Alessandra Gnani, Sabrina Colarossi, et al.
Hematological Oncology|July 21, 2012
Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemiaRoberto Latagliata, Massimo Breccia, Carmen Fava, et al.
Haematologica|March 23, 2010
The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phaseFrancesca Palandri, Fausto Castagnetti, Ilaria Iacobucci, et al.
American Journal of Hematology|June 5, 2025
Outcome of Chronic Myeloid Leukemia Patients Not in Deep Molecular Response: Results From the GIMEMA LabNet CML Network DatabaseFabio Stagno, Rosalba Cucci, Giovanni Marsili, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 4, 2005
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid LeukemiaSimona Soverini, Giovanni Martinelli, Gianantonio Rosti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 5, 2010
Deletions of the derivative chromosome 9 do not influence the response and the outcome of chronic myeloid leukemia in early chronic phase treated with imatinib mesylate: GIMEMA CML Working Party analysisFausto Castagnetti, Nicoletta Testoni, Simona Luatti, et al.
Haematologica|January 16, 2009
The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-upFrancesca Palandri, Fausto Castagnetti, Giuliana Alimena, et al.
Haematologica|July 18, 2012
Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitorsAntonella Russo Rossi, Massimo Breccia, Elisabetta Abruzzese, et al.
Annals of Hematology|April 21, 2018
Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practiceMassimo Breccia, Elisabetta Abruzzese, Fausto Castagnetti, et al.
Pageof 16